{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Taiwan Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/tw/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/tw/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Taiwan, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:f7f9f32faa5757a93cc9c56e089ea2e99b7262c3f1b5448a4fdae7ee9ef1638a", "url": "https://finance.yahoo.com/healthcare/articles/icc-arbitral-tribunal-issues-quantum-174800144.html", "external_url": "https://finance.yahoo.com/healthcare/articles/icc-arbitral-tribunal-issues-quantum-174800144.html", "title": "ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi\u00ae Proceedings", "content_text": "VIENNA, August 07, 2026--(BUSINESS WIRE)--An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (\"AOP Health\") a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (\"PharmaEssentia\") concerning BESREMi\u00ae (ropeginterferon alfa-2b). The award quantifies AOP Health's damage claims for PharmaEssentia's intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022.", "date_published": "2026-08-07T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "6446"], "_sharemaestro": {"country": "Taiwan", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6446", "name": "PharmaEssentia Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/adbc8547-2152-4123-86b9-f5e77c6920f1/"}]}}]}